Valeant Pharm., the company that bought Provenge, lost half its stock market value today. The company was built on acquisitions, not drug discovery, for the most part. Anyway, it is in the news today.
"Shares of Valeant Pharmaceuticals tumbled on Tuesday after the company cut its 2016 revenue forecast by about
12 percent and said a delay in filing its annual report could pose a debt default risk.
The stock closed down more than 51 percent on Tuesday."
The stock has been falling due to fears of accounting irregularities.
Post Edited (RobertC) : 3/15/2016 3:10:21 PM (GMT-6)